Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Treatment of depression and anxiety disorders with selective serotonin reuptake inhibitors (SSRIs) has been shown by numerous studies to be generally effective. Less well understood is how clinically to address the residual anxiety symptoms a significant minority of such patients treated with SSRIs continue to experience. We assessed quetiapine as adjunctive therapy to SSRIs for patients with anxiety symptoms complicating a depressive or anxiety disorder. Patients receiving a stable dosage of an SSRI for at least 6 weeks who also had persistent anxiety symptoms (Hamilton Anxiety scale [HAM-A] > or =16), were enrolled in a 9-week, open-label, variable dose study. Changes in clinical status were assessed with the Hamilton Depression Rating Scale (HAM-D), HAM-A, and State Anxiety Inventory (SAI). Statistically and clinically significant reductions of > or =50% in the HAM-D and HAM-A occurred by the second week of treatment in 10 of the 11 patients. These improvements continued throughout the study along with a significant improvement on the SAI scale. The most frequent side effects reported were mild dry mouth, constipation, and transient drowsiness with dose escalation. The results provide evidence that quetiapine may be an effective adjunctive treatment for recalcitrant anxiety symptoms in individuals treated with SSRIs for either anxiety or depressive disorders. Given the open-label design of the trial, more rigorous studies are clearly indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia
Kapur, S., & Remington, G. (2001) · Annual Review of Medicine · doi:10.1146/annurev.med.52.1.503 · Cited by 324
Stahl, S. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0901 · Cited by 88
Cited by
McIntyre, A., Gendron, A., & McIntyre, A. (2007) · Depression and Anxiety · doi:10.1002/da.20275 · Cited by 145
Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990423 · Cited by 142
Hirschfeld, R. M. A., Weisler, R. H., Raines, S. R., Macfadden, W., & BOLDER Study Group (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0304 · Cited by 116
Carvalho, A. F., Cavalcante, J. L., Castelo, M. S., & Lima, M. C. O. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00846.x · Cited by 110
“Risperidone (95,96), olanzapine (96), quetiapine (97), aripiprazole (98, 99) and ziprasidone (100, 101) have been shown to be effective augmenting agents in small uncontrolled studies in MDD patients, refractory to SSRIs.”
BackgroundGood, C. R. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.235 · Cited by 18
Metadata
- Authors
- Adson, D. E., Kushner, M. G., Eiben, K. M., & Schulz, S. C.
- Venue
- Depression and Anxiety
- Publisher
- Hindawi Limited
- Published
- 2004
- Volume
- 19
- Issue
- 2
- Pages
- 121-126
- ISSN
- 1091-4269 (ISSN-L)
- 1520-6394
- OpenAlex
- W2058966265
- Cited by
- 59
- References
- 2
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. https://app.cochat.ai/papers/10.1002/da.10137
- The paper
- Adson, D. E., Kushner, M. G., Eiben, K. M., & Schulz, S. C. (2004). Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depression and Anxiety. https://doi.org/10.1002/da.10137
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.